Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Region-of-Interest Based Transfer Learning Assisted Framework for Skin Cancer Detection
250
Zitationen
9
Autoren
2020
Jahr
Abstract
Melanoma is considered the most serious type of skin cancer. All over the world, the mortality rate is much high for melanoma in contrast with other cancer. There are various computer-aided solutions proposed to correctly identify melanoma cancer. However, the difficult visual appearance of the nevus makes it very difficult to design a reliable Computer-Aided Diagnosis (CAD) system for accurate melanoma detection. Existing systems either uses traditional machine learning models and focus on handpicked suitable features or uses deep learning-based methods that use complete images for feature learning. The automatic and most discriminative feature extraction for skin cancer remains an important research problem that can further be used to better deep learning training. Furthermore, the availability of the limited available images also creates a problem for deep learning models. From this line of research, we propose an intelligent Region of Interest (ROI) based system to identify and discriminate melanoma with nevus cancer by using the transfer learning approach. An improved k-mean algorithm is used to extract ROIs from the images. These ROI based approach helps to identify discriminative features as the images containing only melanoma cells are used to train system. We further use a Convolutional Neural Network (CNN) based transfer learning model with data augmentation for ROI images of DermIS and DermQuest datasets. The proposed system gives 97.9% and 97.4% accuracy for DermIS and DermQuest respectively. The proposed ROI based transfer learning approach outperforms existing methods that use complete images for classification.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.487 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.112 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.672 Zit.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · 5.808 Zit.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5.362 Zit.